GLIOTHERAPY LIMITED

Company Registration Number:
09604155 (England and Wales)

Unaudited abridged accounts for the year ended 31 May 2024

Period of accounts

Start date: 01 June 2023

End date: 31 May 2024

GLIOTHERAPY LIMITED

Contents of the Financial Statements

for the Period Ended 31 May 2024

Balance sheet
Notes

GLIOTHERAPY LIMITED

Balance sheet

As at 31 May 2024


Notes

2024

2023


£

£
Called up share capital not paid: 0 0
Fixed assets
Intangible assets:   0 0
Tangible assets:   0 0
Investments:   0 0
Total fixed assets: 0 0
Current assets
Stocks: 0 0
Debtors:   0 0
Cash at bank and in hand: 462 77
Investments:   0 0
Total current assets: 462 77
Creditors: amounts falling due within one year:   (16,650) 0
Net current assets (liabilities): (16,188) 77
Total assets less current liabilities: (16,188) 77
Creditors: amounts falling due after more than one year: 3 (19,716) (11,416)
Provision for liabilities: 0 0
Total net assets (liabilities): (35,904) (11,339)
Capital and reserves
Called up share capital: 200,027 200,027
Share premium account: 0 0
Revaluation reserve: 00
Other reserves: 0 0
Profit and loss account: (235,931) (211,366)
Shareholders funds: (35,904) (11,339)

The notes form part of these financial statements

GLIOTHERAPY LIMITED

Balance sheet statements

For the year ending 31 May 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 26 February 2025
and signed on behalf of the board by:

Name: Dr Nigel Parker
Status: Director

The notes form part of these financial statements

GLIOTHERAPY LIMITED

Notes to the Financial Statements

for the Period Ended 31 May 2024

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

Intangible fixed assets and amortisation policy

Investments are initially recorded at cost and subsequently stated at cost less any accumulated impairment losses

Other accounting policies

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. Where the contractual obligations of financial instruments (including share capital) are equivalent to a similar debt instrument, those financial instruments are classed as financial liabilities. Financial liabilities are presented as such in the balance sheet. Finance costs and gains or losses relating to financial liabilities are included in the profit and loss account. Finance costs are calculated so as to produce a constant rate of return on the outstanding liability. Where the contractual terms of share capital do not have any terms meeting the definition of a financial liability then this is classed as an equity instrument. Dividends and distributions relating to equity instruments are debited direct to equity. Compound instruments comprise both a liability and an equity component. At date of issue, the fair value of the liability component is estimated using the prevailing market interest rate for a similar debt instrument. The liability component is accounted for as a financial liability. The residual is the difference between the net proceeds of issue and the liability component (at time of issue). The residual is the equity component, which is accounted for as an equity instrument. The interest expense on the liability component is calculated applying the effective interest rate for the liability component of the instrument. The difference between this amount and any repayments is added to the carrying amount of the liability in the balance sheet.

GLIOTHERAPY LIMITED

Notes to the Financial Statements

for the Period Ended 31 May 2024

2. Employees

2024 2023
Average number of employees during the period 0 0

GLIOTHERAPY LIMITED

Notes to the Financial Statements

for the Period Ended 31 May 2024

3. Creditors: amounts falling due after more than one year note

The loan from Hamesman Ltd is repayable on notice of one year and one day and carries no interest. The Company has two classes of shares being ordinary shares and convertible redeemable preferred ordinary shares. The preferred shares are convertible by the holders into ordinary shares at any time and, after the expiration of four years from the issue date, are redeemable at the election of the holders at an amount equal to the subscription price paid for such shares. Under IAS 32 and IAS 39, the preferred ordinary shares have been assessed as a compound financial instrument with both a debt and an equity component.